Microtrast (Barium Sulfate)

Barium sulfate contains dense, insoluble barium particles that do not absorb into the body. When ingested, the particles line the lumen of the GI tract and strongly attenuate X‑ray photons because of barium’s high atomic number. This creates a bright, radiopaque outline on imaging studies, allowing clinicians to see structural details and abnormalities.

The dose of Microtrast is determined by the prescribing physician based on the specific imaging procedure, patient age, weight, and clinical indication. Typical regimens involve a measured volume of the suspension taken under supervision, but exact quantities must be individualized and documented by the healthcare provider.

Safety data for barium sulfate in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when clearly necessary and after a risk‑benefit assessment by the treating physician. Breastfeeding mothers should consult their clinician before use.

To order Microtrast, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide your institutional or trade credentials. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, then confirms pricing, availability, shipping details, and any necessary import documentation.

Microtrast (barium sulfate) is a non‑ionic, insoluble oral contrast that provides superior radiopacity for GI tract imaging compared with water‑based iodinated agents, which are often used intravenously. Barium offers longer gastric residence and clearer mucosal coating, but it cannot be used when a perforation is suspected, whereas iodinated agents can be administered intravenously for vascular imaging.

Microtrast should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the suspension is well mixed before each use. Do not freeze the suspension, as this may affect particle distribution.

Microtrast is administered orally as a suspension. The patient drinks a measured volume of the prepared suspension under the supervision of a radiology technician or physician, typically after fasting. The amount ingested depends on the imaging protocol, and the patient may be asked to remain upright to facilitate even distribution throughout the GI tract.

The most serious risks include barium impaction, which can cause bowel obstruction and may require medical intervention; aspiration of barium into the lungs leading to pneumonia; and worsening of an existing gastrointestinal perforation. Prompt recognition of these events and appropriate medical management are essential.

Microtrast should be avoided in patients with known hypersensitivity to barium sulfate, suspected or confirmed bowel obstruction, recent gastrointestinal perforation or surgery, and in individuals for whom aspiration risk is high. Clinicians should also exercise caution in pregnant or lactating patients when alternative imaging options are available.